Blood Glucose Monitoring on GLP-1: Do You Need a CGM or Glucometer?

The short answer depends on who you are.

If you have type 2 diabetes and are taking GLP-1 alongside insulin or sulfonylureas, monitoring blood glucose is clinically important — hypoglycaemia risk increases as GLP-1 improves glucose control.

If you are using GLP-1 purely for weight loss and have no diabetes diagnosis, routine blood glucose monitoring at home is probably not necessary. HbA1c at baseline and follow-up covers what you need.

The nuanced answer — who benefits from closer monitoring, which device is right, and what the data actually shows — takes more unpacking.

What GLP-1 Does to Blood Glucose

GLP-1 receptor agonists lower blood glucose through several mechanisms: they stimulate glucose-dependent insulin secretion (only when glucose is elevated), suppress glucagon, and slow gastric emptying. The "glucose-dependent" nature of insulin stimulation is why hypoglycaemia is rare on GLP-1 monotherapy — the medication only increases insulin release when blood sugar is actually raised.

The picture changes when GLP-1 is combined with medications that lower glucose independently of blood sugar levels — particularly insulin and sulfonylureas (glibenclamide, gliclazide). These drugs can cause hypoglycaemia regardless of whether glucose is elevated, and adding GLP-1 to their effects can push glucose dangerously low.

Who Needs to Monitor Blood Glucose

Type 2 diabetes on insulin or sulfonylureas

Monitor. You need baseline readings, post-meal readings, and readings whenever you feel symptomatic (dizzy, shaky, sweaty, confused). Your prescriber should have already discussed dose reduction of your existing medications when starting GLP-1.

Frequency: Multiple daily readings, especially during dose escalation phases.

Type 2 diabetes on GLP-1 monotherapy or with metformin only

Monitoring is less critical but still useful. Metformin does not cause hypoglycaemia. GLP-1 alone does not cause hypoglycaemia in non-insulin-deficient patients. HbA1c at 3 and 6 months is usually sufficient, supplemented by fasting glucose readings a few times per month.

Pre-diabetes (HbA1c 42–47 mmol/mol)

Optional. A glucometer used occasionally to see how meals affect your glucose can be instructive — particularly for understanding which foods spike your blood sugar. Not clinically mandatory, but informative.

No diabetes diagnosis, using GLP-1 for weight loss

Routine home glucose monitoring is not necessary. Annual HbA1c as part of your blood panel (see /guides/glp1-blood-test-panel-uk) is sufficient. The exception is if you develop symptoms consistent with hypoglycaemia — unusual given GLP-1's mechanism, but check if it happens.

CGM vs Glucometer: The Practical Comparison

Continuous Glucose Monitor (CGM)

CGMs like the Abbott Libre 3 or Dexterity sensor sit under the skin and measure interstitial glucose continuously, sending readings to a smartphone every few minutes. The advantage is a complete picture — you see the glucose curve after meals, during exercise, overnight, and during fasting.

For non-diabetic GLP-1 users interested in metabolic health, CGM data can be genuinely interesting: seeing which meals spike glucose, confirming that fasting glucose is stable, and observing the blunting of post-meal peaks that GLP-1 produces. But "interesting" is different from "necessary."

The current evidence does not support routine CGM use in non-diabetic GLP-1 users on clinical grounds. It is an optional upgrade for those deeply engaged with their metabolic data.

Traditional Glucometer

A glucometer requires a finger prick to deposit blood on a test strip. You get a reading within seconds. Cost per test is lower than CGM but requires manual testing whenever you want data.

For GLP-1 users with type 2 diabetes or pre-diabetes who need to track glucose without the cost of continuous monitoring, a reliable glucometer covers the clinical need.

Understanding Your Glucose Readings

Fasting glucose (first thing in the morning, before eating)

• Below 5.6 mmol/L: normal
• 5.6–6.9 mmol/L: impaired fasting glucose (pre-diabetes range)
• 7.0 mmol/L or above: diabetic range; confirm with HbA1c

Post-meal glucose (2 hours after eating)

• Below 7.8 mmol/L: normal
• 7.8–11.0 mmol/L: impaired glucose tolerance
• Above 11.1 mmol/L: diabetic range

What GLP-1 does to these numbers

On semaglutide, post-meal glucose spikes are blunted — partly through slowed gastric emptying, partly through enhanced insulin secretion. Fasting glucose typically falls. The STEP 1 non-diabetic participants saw HbA1c move from 5.6% to 5.4% over 68 weeks — modest but directionally positive.

In diabetic participants, the changes are more dramatic. STEP 2, which studied semaglutide in type 2 diabetes specifically, showed a mean HbA1c reduction of 1.0–1.6 percentage points from baselines around 8.3%.

Signs of Hypoglycaemia to Know

Even on GLP-1 monotherapy in non-diabetic patients, it is worth knowing what low blood glucose feels like:

• Shakiness or tremor
• Sudden sweating, especially cold sweats
• Dizziness or light-headedness
• Confusion or difficulty concentrating
• Rapid heartbeat
• Intense hunger

If you experience these, check your glucose if you have a monitor. Blood glucose below 3.9 mmol/L is hypoglycaemia. Treat with 15–20g of fast-acting carbohydrate (glucose tablets, orange juice) and recheck in 15 minutes.

GLP-1 monotherapy in non-diabetics should not cause hypoglycaemia. If you are experiencing these symptoms repeatedly, contact your prescriber.

The Cost Question

NHS funding for glucose monitoring equipment depends on your diabetes status:

• Type 1 diabetes: CGM is funded for most patients
• Type 2 diabetes on insulin: Finger-prick testing is typically funded; some CGM funding available
• Type 2 diabetes on non-insulin medication: Limited NHS provision; privately purchased monitors common
• Non-diabetic: Not funded; self-purchase required

For those purchasing privately:

• A basic glucometer costs £15–30
• Test strips cost £10–25 for 50
• The Sinocare Safe AQ is one of the most cost-effective options for occasional non-CGM monitoring

CGM sensors cost £40–75 each and last 14 days, putting continuous monitoring at £80–150 per month. For non-diabetic users, this is a significant ongoing cost for data that may be more informative than clinically necessary.

Integrating Glucose Data With Your Wider Monitoring

If you do use a glucometer or CGM, the data has the most value when combined with other tracking:

• Cross-reference glucose readings with your activity log (exercise improves glucose uptake)
• Note which meals cause the largest post-meal spikes (useful for dietary adjustments)
• Track fasting glucose trend alongside weight trend — they should move in the same direction
• Bring your readings to your prescriber; patterns are more useful than isolated readings

For the full GLP-1 monitoring framework, see /guides/glp1-monitoring-protocol. For the blood panel that covers HbA1c and other metabolic markers, see /guides/glp1-blood-test-panel-uk.

Practical Recommendations by Profile

Type 2 diabetic on insulin or sulfonylurea + GLP-1: Monitor fasting glucose daily. Check post-meal readings during dose escalation. CGM is worth considering to catch nocturnal hypoglycaemia. Expect your prescriber to reduce insulin doses as GLP-1 improves glucose control.

Type 2 diabetic on GLP-1 + metformin only: Fasting glucose 2–3 times per week is sufficient. HbA1c at 3 and 6 months. No CGM needed unless you want the data.

Pre-diabetic using GLP-1 for weight and metabolic health: Occasional fasting glucose readings (weekly or fortnightly). HbA1c at 6 months and annually. Consider CGM for 2 weeks at baseline to understand your glucose patterns, then discontinue.

Non-diabetic using GLP-1 for weight loss: HbA1c at baseline and 6 months is sufficient. Home glucose monitoring is optional. If you want to experiment with CGM for metabolic curiosity, go for it — just understand it is not clinically required for you.

For any concerns about your glucose readings or side effects, speak to your prescriber or GP rather than adjusting your medication independently.